Few to no drugs have emerged that impact either the cause or progression of diseases of the central nervous system. Early- and late-stage drug failures, mostly with small molecule drugs and the odd peptide, populate the neurodegenerative disease landscape. Companies have moved away from these types of drugs toward biologics like mAb therapeutics. Those that can successfully develop novel treatments, despite the formidable obstacles to drug development, have a lot to gain. The global market for neurodegenerative treatments will exceed $43.4 billion by 2015, Global Industry Analysts predict. Do you think there will be a breakthrough with mAbs?

Poll Question:
Do you believe mAb therapeutics will be the answer to treating Alzheimer disease?




Previous articlePoll Majority Confident that Massachusetts Can Maintain Biopharma Construction Boom
Next articleTDI Licenses PBI’s Pressure Cycling Technology for Cancer Biomarker Diagnostic Services